Historical Valuation
Cytosorbents Corp (CTSO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.01 is considered Undervalued compared with the five-year average of -10.37. The fair price of Cytosorbents Corp (CTSO) is between 0.75 to 3.29 according to relative valuation methord. Compared to the current price of 0.67 USD , Cytosorbents Corp is Undervalued By 11.08%.
Relative Value
Fair Zone
0.75-3.29
Current Price：0.67
11.08%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Cytosorbents Corp (CTSO) has a current Price-to-Book (P/B) ratio of 4.57. Compared to its 3-year average P/B ratio of 4.09 , the current P/B ratio is approximately 11.66% higher. Relative to its 5-year average P/B ratio of 3.73, the current P/B ratio is about 22.35% higher. Cytosorbents Corp (CTSO) has a Forward Free Cash Flow (FCF) yield of approximately -24.32%. Compared to its 3-year average FCF yield of -30.00%, the current FCF yield is approximately -18.91% lower. Relative to its 5-year average FCF yield of -25.31% , the current FCF yield is about -3.91% lower.
P/B
Median3y
4.09
Median5y
3.73
FCF Yield
Median3y
-30.00
Median5y
-25.31
Competitors Valuation Multiple
AI Analysis for CTSO
The average P/S ratio for CTSO competitors is 2.52, providing a benchmark for relative valuation. Cytosorbents Corp Corp (CTSO.O) exhibits a P/S ratio of 1.01, which is -59.83% above the industry average. Given its robust revenue growth of 10.12%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CTSO
1Y
3Y
5Y
Market capitalization of CTSO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CTSO in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CTSO currently overvalued or undervalued?
Cytosorbents Corp (CTSO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.01 is considered Undervalued compared with the five-year average of -10.37. The fair price of Cytosorbents Corp (CTSO) is between 0.75 to 3.29 according to relative valuation methord. Compared to the current price of 0.67 USD , Cytosorbents Corp is Undervalued By 11.08% .
What is Cytosorbents Corp (CTSO) fair value?
CTSO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Cytosorbents Corp (CTSO) is between 0.75 to 3.29 according to relative valuation methord.
How does CTSO's valuation metrics compare to the industry average?
The average P/S ratio for CTSO's competitors is 2.52, providing a benchmark for relative valuation. Cytosorbents Corp Corp (CTSO) exhibits a P/S ratio of 1.01, which is -59.83% above the industry average. Given its robust revenue growth of 10.12%, this premium appears unsustainable.
What is the current P/B ratio for Cytosorbents Corp (CTSO) as of Jan 10 2026?
As of Jan 10 2026, Cytosorbents Corp (CTSO) has a P/B ratio of 4.57. This indicates that the market values CTSO at 4.57 times its book value.
What is the current FCF Yield for Cytosorbents Corp (CTSO) as of Jan 10 2026?
As of Jan 10 2026, Cytosorbents Corp (CTSO) has a FCF Yield of -24.32%. This means that for every dollar of Cytosorbents Corp’s market capitalization, the company generates -24.32 cents in free cash flow.
What is the current Forward P/E ratio for Cytosorbents Corp (CTSO) as of Jan 10 2026?
As of Jan 10 2026, Cytosorbents Corp (CTSO) has a Forward P/E ratio of -4.14. This means the market is willing to pay $-4.14 for every dollar of Cytosorbents Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Cytosorbents Corp (CTSO) as of Jan 10 2026?
As of Jan 10 2026, Cytosorbents Corp (CTSO) has a Forward P/S ratio of 1.01. This means the market is valuing CTSO at $1.01 for every dollar of expected revenue over the next 12 months.